Clinical support framework
A structured, adjunctive protocol for Sjögren’s syndrome management. No curative claims — focus on immunomodulation, tissue support, and functional improvement.
Eligibility & best candidates
This integrative regenerative protocol is designed for individuals with a confirmed Sjögren’s syndrome diagnosis who meet specific clinical criteria following multidisciplinary evaluation.
- Confirmed diagnosis by rheumatology (ACR/EULAR criteria)
- Mild to moderate systemic or glandular activity
- Stable medical status, no active malignancy
- Absence of severe organ failure (liver, kidney, cardiac)
- No contraindications to cellular or minimally invasive procedures
- Committed to adjunctive physical and nutritional support
Each candidate undergoes an in‑person or telemedicine assessment. Not all applicants are eligible; objective selection ensures appropriate patient care.
Umbilical cord mesenchymal stem cells: core modality
Umbilical cord derived mesenchymal stem cells (UC‑MSCs) are characterized by immunomodulatory properties and low immunogenicity. In the context of Sjögren’s syndrome, they are administered via minimally invasive techniques to support the modulation of aberrant T‑cell and B‑cell responses. The paracrine secretion of growth factors and anti‑inflammatory cytokines (TGF‑β, IL‑10) contributes to a tolerogenic microenvironment. This approach is always integrated with physical therapy to maintain joint function and nutritional medicine to address systemic inflammation. The procedure is performed under strict aseptic protocols. No claim of disease reversal; evidence level: ongoing clinical investigation.
Minimally invasive administration
Cell delivery via targeted, image‑guided injection (when indicated). No surgical incisions. Outpatient recovery.
Supportive therapy integration
Physical medicine and nutritional counseling are titrated to individual needs. No standalone claim; synergy with cell therapy.